Further research data on Dozagliatin were published on CDS 2020

On November 26th, Hua-Li Pharmaceuticals published 24 weeks of further analysis data on the registered clinical study DAWN (also known as HMM0302) of dozagliatin and metformin in CDS 2020.
24-week study data showed that for patients with type 2 diabetes who had failed metformin(1500 mg/day), the dozagliatin treatment group HbA1c was 1.0 lower than the baseline. 2%, 0.66% more than the placebo control group (0.36% in the placebo group), p-value of 0.0001, the drug effect is significant, significantly better than metformin single drug treatment.
Dozagliatin also showed the following characteristics: rapid effectiveness, effective decline of glycated hemoglobin (HbA1c) after 4 weeks of use, significant improvement in cell function in the treatment group's β cells compared to the placebo control group, decreased insulin resistance, significant decrease in blood sugar levels in the 2 hours after meals in the treatment group compared to the placebo control group, safety and tolerance Well, the low rate of hypoglycemia (less than 1% during the 24-week treatment period) . . . more than 24 weeks of sustained effectiveness . . . good response rate In addition, the clinical results of dozagliatin and SGLT-2 inhibitors, combined with major therapeutic drugs such as DPP-4 inhibitors showed that the combined drug had a significant effect on blood sugar control.
clinical trials, Dozagliatin showed positive results in blood sugar control.
Phase III clinical trial analysis of dozagliatin and metformin showed that Dozagliatin showed the following positive prospects for the treatment of type 2 diabetes: Glycoglobin (HbA1c) in the dozagliatin treatment group. ) 1.02% lower than the baseline, better than 0.36% in the placebo control group, with significant statistical significance between groups . . . Dozagliatin showed a high response rate in the treatment group, a response rate of 40% for 8 weeks of treatment, and 24 weeks of treatment Response rate was 44.4% - Significant reduction in blood sugar in 2 hours after meals (5.45mmol/L in the treatment group, 2.98mmol/L, p.lt;001 in the placebo control group) In the first follow-up after starting treatment, the subjects' blood sugar dropped, the rate of hypoglycemia was low, the rate of hypoglycemia was less than 1% for more than 24 weeks, the rate of other adverse events between the treatment group and the placebo control group was similar, measured by THEHOMA2-beta1 index, Dozagliatin showed significant improvements in β cell function, with a 3.77 percent increase in the treatment group and a 1.35 percent increase in the placebo control group. The development history, the differences between Dozagliatin and other GKA, etc., further expounds Dozagliatin as a glucose hypersensitive agent, repairs glucose kinase function, restores the sensitivity of human blood sugar, remodels the stable state of blood sugar, so as to achieve the core scientific concept of the fundamental treatment of diabetes.
。